BACKGROUND: Recurrence of immunoglobulin A nephropathy (IgAN) limits graft survival in kidney transplantation. However, predictors of a worse outcome are poorly understood. METHODS: Among 442 kidney transplant recipients (KTRs) with IgAN, 83 (18.8%) KTRs exhibited biopsy-proven IgAN recurrence between 1994 and 2020 and were enrolled in the derivation cohort. A multivariable Cox model predicting allograft loss based on clinical data at the biopsy and a web-based nomogram were developed. The nomogram was externally validated using an independent cohort (n = 67). RESULTS: Patient age <43 years {hazard ratio [HR] 2.20 [95% confidence interval (CI) 1.41-3.43], P < .001}, female gender [HR 1.72 (95% CI 1.07-2.76), P = .026] and retransplantation status [HR 1.98 (95% CI 1.13-3.36), P = .016] were identified as independent risk factors for IgAN recurrence. Patient age <43 years [HR 2.77 (95% CI 1.17-6.56), P = .02], proteinuria >1 g/24 hours [HR 3.12 (95% CI 1.40-6.91), P = .005] and C4d positivity [HR 2.93 (95% CI 1.26-6.83), P = .013] were found to be associated with graft loss in patients with IgAN recurrence. A nomogram predicting graft loss was constructed based on clinical and histological variables, with a C statistic of 0.736 for the derivation cohort and 0.807 for the external validation cohort. CONCLUSIONS: The established nomogram identified patients with recurrent IgAN at risk for premature graft loss with good predictive performance.

1st Medical Faculty Charles University Prague Czech Republic

Clinical and Transplant Pathology Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Informatics Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Nephrology Oslo University Hospital Oslo Norway

Department of Nephrology Transplant Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Moroni  G, Longhi  S, Quaglini  S  et al.  The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol Dial Transplant  2013;28:1305–14. 10.1093/ndt/gfs472 PubMed DOI

Infante  B, Rossini  M, Di Lorenzo  A  et al.  Recurrence of immunoglobulin A nephropathy after kidney transplantation: a narrative review of the incidence, risk factors, pathophysiology and management of immunosuppressive therapy. Clin Kidney J  2020;13:758–67. 10.1093/ckj/sfaa060 PubMed DOI PMC

Cernoch  M, Hruba  P, Kollar  M  et al.  Intrarenal complement system transcripts in chronic antibody-mediated rejection and recurrent IgA nephropathy in kidney transplantation. Front Immunol  2018;9:2310. 10.3389/fimmu.2018.02310 PubMed DOI PMC

Briganti  EM, Russ  GR, McNeil  JJ  et al.  Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med  2002;347:103–9. 10.1056/NEJMoa013036 PubMed DOI

Moroni  G, Belingheri  M, Frontini  G  et al.  Immunoglobulin A nephropathy. Recurrence after renal transplantation. Front Immunol  2019;10:1332. 10.3389/fimmu.2019.01332 PubMed DOI PMC

Choy  BY, Chan  TM, Lo  SK  et al.  Renal transplantation in patients with primary immunoglobulin A nephropathy. Nephrol Dial Transplant  2003;18:2399–404. 10.1093/ndt/gfg373 PubMed DOI

Sahin  OZ, Yavas  H, Taslı  F  et al.  Prognostic value of glomerular C4d staining in patients with IgA nephritis. Int J Clin Exp Pathol  2014;7:3299–304. PubMed PMC

Tortajada  A, Gutierrez  E, Pickering  MC  et al.  The role of complement in IgA nephropathy. Mol Immunol  2019;114:123–32. 10.1016/j.molimm.2019.07.017 PubMed DOI

Storrar  J, Chinnadurai  R, Sinha  S  et al.  The epidemiology and evolution of IgA nephropathy over two decades: a single centre experience. PLoS One  2022;17:e0268421. 10.1371/journal.pone.0268421 PubMed DOI PMC

Moriyama  T, Tanaka  K, Iwasaki  C  et al.  Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One  2014;9:e91756. 10.1371/journal.pone.0091756 PubMed DOI PMC

Xie  J, Kiryluk  K, Wang  W  et al.  Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One  2012;7:e38904. 10.1371/journal.pone.0038904 PubMed DOI PMC

Berthoux  F, Mohey  H, Laurent  B  et al.  Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol  2011;22:752–61. 10.1681/ASN.2010040355 PubMed DOI PMC

Lv  J, Yang  Y, Zhang  H  et al.  Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol  2013;24:2118. 10.1681/ASN.2012101017 PubMed DOI PMC

Reich  HN, Troyanov  S, Scholey  JW  et al.  Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol  2007;18:3177–83. 10.1681/ASN.2007050526 PubMed DOI

Rodrigues  JC, Haas  M, Reich  HN. IgA nephropathy. Clin J Am Soc Nephrol  2017;12:677–86. 10.2215/CJN.07420716 PubMed DOI PMC

Roberts  IS, Cook  HT, Troyanov  S  et al.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int  2009;76:546–56. 10.1038/ki.2009.168 PubMed DOI

Cattran  DC, Coppo  R, Cook  HT  et al.  The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int  2009;76:534–45. 10.1038/ki.2009.243 PubMed DOI

Trimarchi  H, Barratt  J, Cattran  DC  et al.  Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int  2017;91:1014–21. 10.1016/j.kint.2017.02.003 PubMed DOI

Jiang  SH, Kennard  AL, Walters  GD. Recurrent glomerulonephritis following renal transplantation and impact on graft survival. BMC Nephrol  2018;19:344. 10.1186/s12882-018-1135-7 PubMed DOI PMC

McDonald  SP, Russ  GR. Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches. Transplantation  2006;82:759–62. 10.1097/01.tp.0000230131.66971.45 PubMed DOI

Clayton  P, McDonald  S, Chadban  S. Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transplant  2011;11:1645–9. 10.1111/j.1600-6143.2011.03667.x PubMed DOI

Allen  PJ, Chadban  SJ, Craig  JC  et al.  Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes. Kidney Int  2017;92:461–9. 10.1016/j.kint.2017.03.015 PubMed DOI

Cosio  FG, Cattran  DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int  2017;91:304–14. 10.1016/j.kint.2016.08.030 PubMed DOI

Capanu  M, Gönen  M. Building a nomogram for survey-weighted cox models using R. J Stat Softw Code Snippets  2015;64:1–17.

Zhang  J, Chen  GD, Qiu  J  et al.  Graft failure of IgA nephropathy in renal allografts following living donor transplantation: predictive factor analysis of 102 biopsies. BMC Nephrol  2019;20:446. 10.1186/s12882-019-1628-z PubMed DOI PMC

Avasare  RS, Rosenstiel  PE, Zaky  ZS  et al.  Predicting post-transplant recurrence of IgA nephropathy: the importance of crescents. Am J Nephrol  2017;45:99–106. 10.1159/000453081 PubMed DOI PMC

Uffing  A, Pérez-Saéz  MJ, Jouve  T  et al.  Recurrence of IgA nephropathy after kidney transplantation in adults. Clin J Am Soc Nephrol  2021;16:1247–55. 10.2215/CJN.00910121 PubMed DOI PMC

Jäger  C, Stampf  S, Molyneux  K  et al.  Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study. BMC Nephrol  2022;23:178. 10.1186/s12882-022-02802-x PubMed DOI PMC

Berthoux  F, El Deeb  S, Mariat  C  et al.  Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. Transplantation  2008;85:1505–7. 10.1097/TP.0b013e3181705ad4 PubMed DOI

Yu  G, Cheng  J, Jiang  Y  et al.  Intensive systolic blood pressure lowering and kidney disease progression in IgA nephropathy: a cohort study. Front Med (Lausanne)  2022;9:813603. 10.3389/fmed.2022.813603 PubMed DOI PMC

Ptinopoulou  AG, Pikilidou  MI, Lasaridis  AN. The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review. Hypertens Res  2013;36:91–101. 10.1038/hr.2012.157 PubMed DOI

Kanno  Y, Okada  H, Saruta  T  et al.  Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin Nephrol  2000;54:360–5. PubMed

Espinosa  M, Ortega  R, Gómez-Carrasco  JM  et al.  Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. Nephrol Dial Transplant  2009;24:886–91. 10.1093/ndt/gfn563 PubMed DOI

Maillard  N, Wyatt  RJ, Julian  BA  et al.  Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol  2015;26:1503–12. 10.1681/ASN.2014101000 PubMed DOI PMC

Faria  B, Canão  P, Cai  Q  et al.  Arteriolar C4d in IgA nephropathy: a cohort study. Am J Kidney Dis  2020;76:669–78. 10.1053/j.ajkd.2020.03.017 PubMed DOI

Espinosa  M, Ortega  R, Sánchez  M  et al.  Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol  2014;9:897–904. 10.2215/CJN.09710913 PubMed DOI PMC

O'Shaughnessy  MM, Liu  S, Montez-Rath  ME  et al.  Kidney transplantation outcomes across GN subtypes in the United States. J Am Soc Nephrol  2017;28:632–44. 10.1681/ASN.2016020126 PubMed DOI PMC

Eder  M, Kozakowski  N, Omic  H  et al.  Glomerular C4d in post-transplant IgA nephropathy is associated with decreased allograft survival. J Nephrol  2021;34:839–49. PubMed PMC

Mengel  M, Bogers  J, Bosmans  J-L  et al.  Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant  2005;5:1050–6. 10.1111/j.1600-6143.2005.00788.x PubMed DOI

Haas  M, Sis  B, Racusen  LC  et al.  Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant  2014;14:272–83. PubMed

Senev  A, Coemans  M, Lerut  E  et al.  Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome. Am J Transplant  2019;19:763–80. 10.1111/ajt.15074 PubMed DOI

Coppo  R, Troyanov  S, Bellur  S  et al.  Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int  2014;86:828–36. 10.1038/ki.2014.63 PubMed DOI PMC

Park  S, Go  H, Baek  CH  et al.  Clinical importance of the updated Oxford classification in allograft IgA nephropathy. Am J Transplant  2019;19:2855–64. 10.1111/ajt.15400 PubMed DOI

Liu  J, Duan  S, Chen  P  et al.  Development and validation of a prognostic nomogram for IgA nephropathy. Oncotarget  2017;8:94371–81. 10.18632/oncotarget.21721 PubMed DOI PMC

Liu  L-L, Zhu  L-B, Zheng  J-N  et al.  Development and assessment of a predictive nomogram for the progression of IgA nephropathy. Sci Rep  2018;8:7309. PubMed PMC

Li  F, Wei  RB, Wang  Y  et al.  Nomogram prediction model for renal anaemia in IgA nephropathy patients. Open Med (Wars)  2021;16:718–27. 10.1515/med-2021-0284 PubMed DOI PMC

Barbour  SJ, Coppo  R, Zhang  H  et al.  Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med  2019;179:942–52. 10.1001/jamainternmed.2019.0600 PubMed DOI PMC

Heerspink  HJL, Stefánsson  BV, Correa-Rotter  R  et al.  Dapagliflozin in patients with chronic kidney disease. N Engl J Med  2020;383:1436–46. 10.1056/NEJMoa2024816 PubMed DOI